Lescarden Inc.
LCAR
Other OTC0.00
USD
- -
- -
Return %
Stock
S&P500
1Y
-99.00
19.01
3Y
-99.00
65.48
5Y
-99.00
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- William E. Luther
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 420 Lexington Avenue New York City NY United States of America 10170
- IPO Date
- Jan 4, 1999
- Website
- lescarden.com
- Similar Companies
- Business
- Lescarden Inc. (LCAR) researches, develops, tests and sells biologic materials and medications focused on wound healing, skin care, osteoarthritis and cancer treatments. The company offers Catrix Wound Dressing, a bovine cartilage powder approved by the FDA for managing chronic wounds such as decubitus ulcers, venous stasis ulcers, diabetic ulcers, second-degree burns and post-radiation dermatitis; Catrix-based skin care products for plastic surgery, dermatology and medical-spa applications; nutritional supplements including Bio-Cartilage and Poly-NAG, a patented glucosamine polymer. It operates in the United States, with products manufactured by FDA-approved facilities domestically and in Iceland, and pursues markets in Europe, South Korea and the Western Pacific region. Founded in 1960 and headquartered in New York, the company licenses its technologies and faces regulation from U.S. federal, state and international authorities. Recent financial statements indicate zero sales, assets and cash flows as of October 2025, signaling minimal active operations amid a competitive biotech landscape.